Manufacturing Quality Standards

AUREX compounds are manufactured in cGMP-compliant US laboratories following ICH Q7 guidelines for active pharmaceutical ingredient production. Here is what that means at each stage of the manufacturing process.

Solid-Phase Peptide Synthesis (SPPS): We use Fmoc (fluorenylmethyloxycarbonyl) chemistry — the modern standard that operates under mild base conditions for deprotection, avoiding the repeated strong acid exposure required by older Boc (tert-butyloxycarbonyl) methods. Each amino acid is coupled to the resin-bound growing chain using activating reagents (typically HBTU or HATU), with real-time coupling efficiency monitored via UV absorbance of the Fmoc-piperidine adduct. Target coupling efficiency exceeds 99.5% per cycle — critical because even 99% efficiency across a 30-residue sequence yields only 74% full-length product.

Cleavage and deprotection: After synthesis, the completed peptide is cleaved from the resin using trifluoroacetic acid (TFA) with a scavenger cocktail optimized for each sequence. Scavenger selection (triisopropylsilane, water, ethanedithiol, anisole) depends on the side-chain protecting groups present — incorrect scavenger ratios cause alkylation side reactions that produce difficult-to-remove impurities.

Multi-stage purification: Crude peptide undergoes preparative reversed-phase HPLC using C18 columns with water/acetonitrile gradients. This separates the target full-length sequence from truncated sequences (coupling failures), deletion products (deprotection failures), and oxidized variants. For complex sequences, a second orthogonal purification step using different column chemistry or gradient conditions may be employed to achieve the target purity.

Lyophilization: Purified fractions are pooled, flash-frozen in liquid nitrogen or dry ice/acetone baths, and freeze-dried under controlled vacuum (typically below 100 mTorr). The temperature ramp profile during primary and secondary drying phases is optimized per compound to preserve molecular structure. The resulting lyophilized cake should appear as a uniform white to off-white powder — collapse, discoloration, or melt-back indicate process deviations.

Quality Control: Every batch undergoes a panel of analytical tests: reversed-phase HPLC at 214nm and 280nm for purity assessment, ESI-MS for molecular identity confirmation (observed mass within 0.02 Da of theoretical), endotoxin testing via LAL (Limulus Amebocyte Lysate) assay for biological research applications, residual solvent analysis per ICH Q3C guidelines, and water content by Karl Fischer titration. Results that fall outside specification trigger automatic batch rejection.

cGMP Compliance: Current Good Manufacturing Practice regulations per 21 CFR Parts 210/211 ensure consistency through documented Standard Operating Procedures, validated equipment with regular calibration schedules, environmental monitoring of clean rooms, trained personnel with documented competency assessments, complete batch records with full traceability from raw amino acids to finished product, and formal deviation and CAPA (Corrective and Preventive Action) systems.

Third-party verification: AUREX uses independent analytical laboratories for all quality assessments. In-house testing creates inherent conflicts of interest — the same organization that profits from selling a compound should not be the sole arbiter of its quality. Independent labs operate under their own quality systems and have no financial stake in the results.